Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE vs BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Buprenorphine is a partial mu-opioid receptor agonist and a weak kappa-opioid receptor antagonist; naloxone is a mu-opioid receptor antagonist that is added to deter intravenous abuse.
Partial mu-opioid receptor agonist (buprenorphine) and mu-opioid receptor antagonist (naloxone). Buprenorphine has high affinity but low intrinsic activity at mu receptors, producing ceiling effects on respiratory depression and euphoria. Naloxone antagonizes opioid effects and is poorly absorbed sublingually, added to discourage parenteral abuse.
Treatment of opioid dependence (FDA-approved),Maintenance therapy for opioid use disorder,Off-label: chronic pain management (limited use)
Treatment of opioid dependence (FDA-approved),Off-label: chronic pain (buprenorphine alone)
Sublingual tablet: initially 2/0.5 mg buprenorphine/naloxone, titrated to maintenance 4/1 mg to 24/6 mg once daily; administered sublingually as a single daily dose.
Sublingual: 2/0.5 mg to 4/1 mg once daily initially; titrate up to 8/2 mg, 12/3 mg, or 16/4 mg once daily; maximum 24/6 mg once daily. Buccal: 2.1/0.3 mg once daily initially; titrate up to 4.2/0.7 mg, 8.4/1.4 mg, or 12.6/2.1 mg once daily; maximum 12.6/2.1 mg once daily.
Buprenorphine: terminal half-life 24-60 hours (mean ~37h) due to slow dissociation from mu-opioid receptors; naloxone: ~2-12 hours (mean ~1-2h IV, slightly longer sublingual).
Buprenorphine: terminal half-life 24-60 hours (mean ~37 h) due to slow dissociation from opioid receptors; clinically relevant for once-daily or alternate-day dosing. Naloxone: terminal half-life 1-2 hours; rapid elimination limits oral systemic availability.
Buprenorphine is primarily metabolized by CYP3A4 to norbuprenorphine; naloxone is metabolized by UDP-glucuronosyltransferases (UGT1A1, UGT1A3).
Primarily via N-dealkylation by CYP3A4 to norbuprenorphine (active metabolite); also glucuronidation by UGT1A1, UGT2B7, UGT1A3. Naloxone is extensively metabolized in the liver, primarily by glucuronidation.
Buprenorphine: ~70% fecal via biliary excretion, ~30% renal as unchanged drug and metabolites. Naloxone: primarily hepatic metabolism, ~50% renal excretion of metabolites within 6h.
Buprenorphine: primarily fecal (69-70%) via biliary excretion; renal (10-30%) as unchanged drug and metabolites. Naloxone: extensively metabolized in liver, primarily conjugated; renal excretion of metabolites (70%), minimal unchanged (<1%).
Buprenorphine: ~96% bound to alpha- and beta-globulins; naloxone: ~45% bound to albumin (primarily).
Buprenorphine: ~96% bound primarily to alpha- and beta-globulins, also to albumin. Naloxone: ~45% bound to plasma proteins (mainly albumin).
Buprenorphine: Vd ~2.5-4.0 L/kg (large distribution due to lipophilicity); naloxone: Vd ~2.0 L/kg.
Buprenorphine: Vd ~3-5 L/kg; high due to lipophilicity and extensive tissue distribution. Naloxone: Vd ~2 L/kg; moderate distribution.
Sublingual buprenorphine: ~30-50% (avoid first-pass); sublingual naloxone: ~10% (low); IV: 100% both.
Sublingual buprenorphine: ~30-50% (range 15-70%). Oral buprenorphine: <10% due to first-pass metabolism. Sublingual naloxone: <2% due to extensive first-pass; negligible under normal conditions, but sufficient to precipitate withdrawal if injected.
For GFR <30 m L/min: use with caution, dose reduction may be necessary; avoid in severe impairment (creatinine clearance <15 m L/min) due to naloxone accumulation.
No dose adjustment required for mild-moderate renal impairment (GFR >=30 m L/min). For severe renal impairment (GFR <30 m L/min), initiate with low doses and titrate cautiously; buprenorphine is highly protein bound but naloxone may accumulate.
Child-Pugh Class A: no adjustment. Child-Pugh Class B: reduce starting dose by 50%, monitor for oversedation. Child-Pugh Class C: not recommended.
Child-Pugh A: no adjustment. Child-Pugh B: use lower initial doses (e.g., 2/0.5 mg sublingual) and titrate slowly. Child-Pugh C: contraindicated due to risk of accumulation and prolonged effects.
Not approved for pediatric patients under 16 years for opioid use disorder; safety and efficacy not established.
Approved for ages >=16 years: dosing same as adults, but start at lowest possible dose (e.g., 2/0.5 mg sublingual) and titrate based on response. For <16 years: safety and efficacy not established.
Initiate at lower end of dosing range (e.g., 2/0.5 mg sublingually once daily) due to increased sensitivity and potential for hepatic/renal impairment; titrate slowly and monitor for CNS depression.
Use with caution; start at low end of dosing range (e.g., 2/0.5 mg sublingual) and titrate slowly due to increased sensitivity, risk of respiratory depression, falls, and cognitive impairment. Monitor renal and hepatic function.
Risk of respiratory depression, particularly in patients using other CNS depressants, and risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy.
Risk of serious respiratory depression, especially during initiation or dose escalation. Concomitant use with CNS depressants (e.g., benzodiazepines, alcohol) may lead to profound sedation, respiratory depression, coma, and death. Neonatal opioid withdrawal syndrome may occur if used during pregnancy. Accidental ingestion, especially by children, can cause fatal respiratory depression.
Respiratory depression risk with intravenous administration,Hepatotoxicity (elevated liver enzymes, hepatic failure),Adrenal insufficiency with chronic use,Interaction with benzodiazepines and other CNS depressants,Precipitation of withdrawal in opioid-dependent patients if administered too soon after last opioid use,Dependence and abuse potential (Schedule III controlled substance),Neonatal opioid withdrawal syndrome if used during pregnancy
Risk of respiratory depression, misuse/abuse, dependence, and withdrawal if abruptly discontinued. Adrenal insufficiency, hepatotoxicity (rare), QTc prolongation (buprenorphine high doses), and precipitation of withdrawal if given too soon after full agonist opioids. Use caution in patients with hepatic impairment, biliary tract disease, or head injury.
Hypersensitivity to buprenorphine or naloxone,Severe respiratory insufficiency (e.g., acute asthma, COPD),Severe hepatic impairment,Patients with acute intoxication (alcohol, opioids, benzodiazepines),Concurrent use of MAO inhibitors (relative contraindication)
Hypersensitivity to buprenorphine or naloxone. Significant respiratory depression. Acute or severe bronchial asthma. Known or suspected gastrointestinal obstruction. Concomitant use with MAOIs or within 14 days of MAOI use (relative).
No significant food interactions; grapefruit juice may increase buprenorphine levels but not considered clinically relevant; alcohol is contraindicated due to additive CNS depression; take on an empty stomach or with food if GI upset occurs.
No specific food interactions. Grapefruit juice may increase buprenorphine levels via CYP3A4 inhibition; avoid excessive consumption. Avoid alcohol-containing foods or beverages due to additive CNS depression.
Pregnancy category C: First trimester: Limited data; no clear evidence of major malformations, but opioid exposure may be associated with neural tube defects in some studies. Second and third trimesters: Risk of neonatal opioid withdrawal syndrome (NOWS) with chronic use. No known specific teratogenicity; however, maternal opioid use may lead to fetal growth restriction, preterm birth, and stillbirth. Buprenorphine/naloxone is preferred over methadone in pregnancy due to less neonatal respiratory depression and NOWS severity.
Pregnancy Category C. First trimester: Limited human data; animal studies show reduced fetal growth and increased fetal loss at high doses. Second and third trimesters: Chronic exposure may cause neonatal opioid withdrawal syndrome (NOWS) and respiratory depression at delivery. Not associated with major malformations.
Limited data; buprenorphine and naloxone are excreted into breast milk in low concentrations. The M/P ratio for buprenorphine is approximately 0.5–2.5, with high interindividual variability. Naloxone has poor oral bioavailability, reducing infant exposure. Benefits of breastfeeding likely outweigh risks if mother is stable on treatment. Monitor infant for sedation, respiratory depression, and adequate weight gain. Avoid use during breastfeeding in cases of high maternal doses or concurrent substance abuse.
Buprenorphine is excreted in breast milk with an estimated average infant dose of 1-2% of maternal weight-adjusted dose. Naloxone has poor oral bioavailability. M/P ratio: buprenorphine ~0.6-1.0. Generally considered compatible with breastfeeding, but monitor infant for drowsiness, respiratory depression, and feeding difficulties.
Pregnancy may require dose increases due to increased plasma volume, enhanced clearance, and changes in protein binding. Buprenorphine is extensively metabolized by CYP3A4, which may be induced during pregnancy. Aim to maintain trough levels to prevent withdrawal. Usually, doses are adjusted based on clinical response (withdrawal symptoms, cravings). No fixed dose adjustment; individual titration is necessary. Higher doses (up to 50% increase) may be needed in late pregnancy. Postpartum, doses should be tapered back to prepregnancy levels gradually.
No standard dose adjustment required in pregnancy, but pharmacokinetic changes (increased clearance, volume of distribution) may necessitate splitting total daily dose into 3-4 doses to avoid withdrawal symptoms. Individualize based on clinical response and signs of withdrawal.
Avoid in patients with known respiratory insufficiency or acute opioid intoxication; use with caution in hepatic impairment; buprenorphine has a ceiling effect for respiratory depression; naloxone component prevents IV abuse; monitor for precipitated withdrawal if initiated too soon after last opioid use; requires at least 12 hours since last short-acting opioid or 24-72 hours for long-acting opioids; can cause QT prolongation at high doses; sublingual absorption is critical; consider dose adjustment in renal impairment.
Buprenorphine/naloxone is a partial mu-opioid agonist with a ceiling effect on respiratory depression, reducing abuse potential but requiring careful induction in opioid-dependent patients to avoid precipitated withdrawal. Sublingual administration bypasses first-pass metabolism; naloxone has poor sublingual bioavailability but precipitates withdrawal if injected parenterally. Monitor hepatic function due to rare hepatotoxicity. Avoid use in severe hepatic impairment. The combination is preferred over buprenorphine alone to deter diversion. Dose adjustments may be needed in renal impairment. Pregnancy: not recommended unless benefit outweighs risk; can cause neonatal opioid withdrawal syndrome.
Place the tablet/film under the tongue until fully dissolved; do not chew, swallow, or crush.,Do not use alcohol or other sedatives (benzodiazepines, muscle relaxants, sleeping pills) as this can cause severe respiratory depression or coma.,Keep out of reach of children and pets; accidental ingestion is life-threatening.,Avoid driving or operating machinery until you know how the medication affects you.,Do not stop suddenly; withdrawal symptoms can occur; taper under medical supervision.,Store at room temperature away from moisture and heat.,Tell all healthcare providers you are taking this medication before any surgery or new prescriptions.,Seek emergency help if you experience difficulty breathing, chest pain, or signs of allergic reaction (rash, swelling).,If you miss a dose, skip it; do not double dose.
Take this medication exactly as prescribed under the tongue; do not chew or swallow it.,Do not inject or snort the medication; this can cause severe withdrawal or overdose.,Avoid alcohol and other central nervous system depressants (e.g., benzodiazepines) as they increase risk of respiratory depression.,Store the medication securely and out of reach of children; properly dispose of unused medication via a take-back program.,Do not stop abruptly; withdrawal symptoms may occur. Follow your provider's tapering plan.,Inform all healthcare providers that you are taking this medication.,Seek emergency care if you experience difficulty breathing, severe drowsiness, or signs of allergic reaction.,This medication is part of a comprehensive treatment plan including counseling and behavioral therapy.
"Cobicistat is a potent CYP3A4 inhibitor used to boost the pharmacokinetics of antiretroviral agents like atazanavir and darunavir. Naloxone primarily undergoes glucuronidation via UGT1A6 and UGT2B7, with minor CYP3A4 metabolism. Concomitant use with Cobicistat may modestly increase naloxone exposure due to CYP3A4 inhibition, but this is unlikely to be clinically significant given naloxone's wide therapeutic index and short half-life."
"Fluvoxamine, a selective serotonin reuptake inhibitor (SSRI), is primarily metabolized by cytochrome P450 (CYP) 1A2 and 2D6. Naloxone, an opioid antagonist, is reported to inhibit CYP1A2, potentially decreasing the clearance of fluvoxamine. This interaction may lead to increased fluvoxamine plasma concentrations, elevating the risk of serotonin syndrome, QT prolongation, and other dose-dependent adverse effects, especially in patients receiving high doses or those with hepatic impairment."
"Naloxone, an opioid receptor antagonist, may inhibit the cytochrome P450 isoenzyme CYP3A4, which is responsible for the metabolism of ivacaftor. Concomitant administration can lead to reduced clearance of ivacaftor, resulting in elevated serum concentrations. This increase may potentiate the therapeutic effects and adverse reactions of ivacaftor, such as hepatotoxicity and QT prolongation."
"Cobicistat is a potent CYP3A4 inhibitor used to boost the pharmacokinetics of antiretroviral agents like atazanavir and darunavir. Naloxone primarily undergoes glucuronidation via UGT1A6 and UGT2B7, with minor CYP3A4 metabolism. Concomitant use with Cobicistat may modestly increase naloxone exposure due to CYP3A4 inhibition, but this is unlikely to be clinically significant given naloxone's wide therapeutic index and short half-life."
"Fluvoxamine, a selective serotonin reuptake inhibitor (SSRI), is primarily metabolized by cytochrome P450 (CYP) 1A2 and 2D6. Naloxone, an opioid antagonist, is reported to inhibit CYP1A2, potentially decreasing the clearance of fluvoxamine. This interaction may lead to increased fluvoxamine plasma concentrations, elevating the risk of serotonin syndrome, QT prolongation, and other dose-dependent adverse effects, especially in patients receiving high doses or those with hepatic impairment."
"Naloxone, an opioid receptor antagonist, may inhibit the cytochrome P450 isoenzyme CYP3A4, which is responsible for the metabolism of ivacaftor. Concomitant administration can lead to reduced clearance of ivacaftor, resulting in elevated serum concentrations. This increase may potentiate the therapeutic effects and adverse reactions of ivacaftor, such as hepatotoxicity and QT prolongation."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE vs BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE, answered by our medical review team.
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE is a Opioid Antagonist that works by Buprenorphine is a partial mu-opioid receptor agonist and a weak kappa-opioid receptor antagonist; naloxone is a mu-opioid receptor antagonist that is added to deter intravenous abuse.. BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE is a Opioid Antagonist that works by Partial mu-opioid receptor agonist (buprenorphine) and mu-opioid receptor antagonist (naloxone). Buprenorphine has high affinity but low intrinsic activity at mu receptors, producing ceiling effects on respiratory depression and euphoria. Naloxone antagonizes opioid effects and is poorly absorbed sublingually, added to discourage parenteral abuse.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE and BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE depend on the specific clinical indication. These are both Opioid Antagonist agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE is: Sublingual tablet: initially 2/0.5 mg buprenorphine/naloxone, titrated to maintenance 4/1 mg to 24/6 mg once daily; administered sublingually as a single daily dose.. The standard adult dose of BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE is: Sublingual: 2/0.5 mg to 4/1 mg once daily initially; titrate up to 8/2 mg, 12/3 mg, or 16/4 mg once daily; maximum 24/6 mg once daily. Buccal: 2.1/0.3 mg once daily initially; titrate up to 4.2/0.7 mg, 8.4/1.4 mg, or 12.6/2.1 mg once daily; maximum 12.6/2.1 mg once daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE and BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE. Cobicistat is a potent CYP3A4 inhibitor used to boost the pharmacokinetics of antiretroviral agents like atazanavir and darunavir. Naloxone primarily undergoes glucuronidation via UGT1A6 and UGT2B7, with minor CYP3A4 metabolism. Concomitant use with Cobicistat may modestly increase naloxone exposure due to CYP3A4 inhibition, but this is unlikely to be clinically significant given naloxone's wide therapeutic index and short half-life. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE is classified as Category A/B. Pregnancy category C: First trimester: Limited data; no clear evidence of major malformations, but opioid exposure may be associated with neural tube defects in some studies. Secon. BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE is classified as Category A/B. Pregnancy Category C. First trimester: Limited human data; animal studies show reduced fetal growth and increased fetal loss at high doses. Second and third trimesters: Chronic exp. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.